Anthracyclines such as doxorubicin are among the most potent chemotherapies and form the backbone of regimens used to treat multiple cancers. While cancer affects more than one in three people over their lifetime, improved long-term cancer survival has led to an increase in the incidence of adverse cardiac side-effects of cancer treatments. Importantly, while > 50% of children afflicted with cancer are treated with anthracyclines, and > 50% of childhood cancer survivors have experienced cardiotoxic effects of chemotherapy. In parallel, > 15% of adult patients with cardiomyopathy have a history significant for cancer treatment during childhood or adolescence. Furthermore, our incomplete understanding of the disease process is highlighted by a glaring absence of personalized, patient-level recommendations to detect cardiotoxicity. Taken together, these data highlight the critical need to develop a deeper understanding of the pathobiology of anthracycline-induced cardiotoxicity, scrutinize established and emerging imaging approaches for cardiotoxicity detection, and explore clinical approaches to disease detection and management.
To this end, we propose the following topics to be covered by lead scientists in basic, translational, and clinical review articles.
1) Novel mechanisms of anthracycline-induced cardiotoxicity.
2) Genetics of anthracycline-induced cardiotoxicity.
3) Echocardiographic assessment of anthracycline-induced cardiotoxicity.
4) Cardiac MRI assessment of anthracycline-induced cardiotoxicity.
5) Cardiac CT assessment of anthracycline-induced cardiotoxicity.
6) Molecular and nuclear imaging assessment of anthracycline-induced cardiotoxicity.
7) Exercise Oncology.
8) Novel heart failure therapies for anthracycline-induced cardiotoxicity.
Anthracyclines such as doxorubicin are among the most potent chemotherapies and form the backbone of regimens used to treat multiple cancers. While cancer affects more than one in three people over their lifetime, improved long-term cancer survival has led to an increase in the incidence of adverse cardiac side-effects of cancer treatments. Importantly, while > 50% of children afflicted with cancer are treated with anthracyclines, and > 50% of childhood cancer survivors have experienced cardiotoxic effects of chemotherapy. In parallel, > 15% of adult patients with cardiomyopathy have a history significant for cancer treatment during childhood or adolescence. Furthermore, our incomplete understanding of the disease process is highlighted by a glaring absence of personalized, patient-level recommendations to detect cardiotoxicity. Taken together, these data highlight the critical need to develop a deeper understanding of the pathobiology of anthracycline-induced cardiotoxicity, scrutinize established and emerging imaging approaches for cardiotoxicity detection, and explore clinical approaches to disease detection and management.
To this end, we propose the following topics to be covered by lead scientists in basic, translational, and clinical review articles.
1) Novel mechanisms of anthracycline-induced cardiotoxicity.
2) Genetics of anthracycline-induced cardiotoxicity.
3) Echocardiographic assessment of anthracycline-induced cardiotoxicity.
4) Cardiac MRI assessment of anthracycline-induced cardiotoxicity.
5) Cardiac CT assessment of anthracycline-induced cardiotoxicity.
6) Molecular and nuclear imaging assessment of anthracycline-induced cardiotoxicity.
7) Exercise Oncology.
8) Novel heart failure therapies for anthracycline-induced cardiotoxicity.
